



Background: The objective of this study was to perform the analytical evaluation of the clinical chemistry analyzer Olympus AU2700 plus. The eva-
luation was performed according to the guidelines of the European Committee for Clinical Laboratory Standards (ECCLS).
Materials and methods: The evaluation consisted of determination of within-run and between-run imprecision, inaccuracy and comparison with 
Olympus AU2700. The tested analytes were: glucose, creatinine, urate, total bilirubin, cholesterol, tryglicerides, calcium, phosphate, iron, unsatura-
ted iron binding capacity, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, creatine kinase, alpha-amylase, alkaline 
phosphatase, potassium, sodium, chloride, C-reactive protein, antistreptolysin O and rheumatoid factor.
Results: The results showed low within-run and between-run imprecision and acceptable inaccuracy for all analytes. High correlation with AU2700 
analyzer was found. Intercept and slope (with 95% con7 dence interval) met the preferences of Passing-Bablok regression for all of the analytes 
except alanine aminotransferase, sodium, rheumatoid factor, creatine kinase, total bilirubin and tryglicerides.
Conclusions: Olympus AU2700 plus analyzer shows acceptable precision and accuracy for majority of analytes, with the exception of sodium and 
chloride. Instrument is fully comparable with Olympus AU2700 analyzer for all but several analytes (ALT, RF, sodium, CK, total bilirubin and tryglice-
rides), where only some minor deviations (constant and proportional di> erence) were observed.
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Olympus AU2700 plus (Olympus CO Ltd., Tokyo, 
Japan) is the new Olympus platform designed for 
clinical chemistry laboratories with large number 
of samples. Analytical evaluation of Olympus 
AU2700 plus analyzer was conducted upon the arri-
val of the analyzer at Clinical Department for Labo-
ratory Diagnostic, Dubrava University Hospital, 
according to the protocol of the European Commi-
ttee for Clinical Laboratory Standards (ECCLS) (1).
Analytical evaluation of the analyzer and methods 
should be done before the introduction of the 
new analyzer into the routine use in order to con-
M rm declared speciM cations of the analytical met-
hods (2–4).
Olympus AU2700 is an automated, multi-channel, 
selective analyzer where the measurements are 
carried out using the spectrophotometry, turbidi-
metry and indirect potentiometry (using ion-se-
lective electrode - ISE unit) in serum, urine, cere-
brospinal R uid, and other types of body R uids. 
Analyzer can process 1600 tests per hour, inclu-
ding 270 ISE unit tests on the working temperatu-
re of 37 ± 0.3 °C. It is possible to program 99 di[ e-
rent analyses at most. Analyzer can process 51 
analyses simultaneously (48 di[ erent analysis and 
3 electrolytes analysis on ISE unit). Olympus 
AU2700 plus has the same settings as the Olympus 
AU2700. Reagents are one- or two-component, lo-
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cated in two separate thermostated containers 
(4-12 °C). Analyzer uses the original reagents that 
are recognized using barcode readers or reagents 
from other manufacturers that are placed into spe-
ciM c positions in the reagent containers. Type of 
reaction determines the number of reagents used 
for the speciM c test. Samples are pipetted using a 
mechanical arm with two needles, which enables 
simultaneous pipetting in two parallel cuvettes. 
Analyzer has the possibility of continuous control 
monitoring, and statistical data processing obtai-
ned during operation (daily control and day-to-
day control).
In this study we aimed to assess the analytical per-
formance of 22 analytes determined on Olympus 
AU2700 plus analyzer (Beckman Coulter, Tokyo, Ja-
pan). For these analytes, a comparison with the Ol-
ympus AU2700 analyzer (Olympus CO Ltd.,Tokyo, 
Japan) was also done.
Materials and methods
Methods
The tested analytes were as follows: glucose, crea-
tinine (Creat), urate, total bilirubin (Bil), cholesterol 
(Chol), tryglicerides (TG), calcium (Ca), phosphate 
(IP), iron (Fe), unsaturated iron binding capacity 
(UIBC), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), lactate dehidrogenase 
(LD), creatine kinase (CK), alpha-amylase (AMY), al-
kaline phosphatase (AP), potassium (K), sodium 
(Na), chloride (Cl), C-reactive protein (CRP), anti-
streptolysin O (ASO) and rheumatoid factor (RF). 
Testing was conducted at the Clinical Department 
for Laboratory Diagnostics, University Hospital Du-
brava, Zagreb, Croatia. Olympus Life and Material 
Science Europa GmbH reagents (Hamburg, Ger-
many) and reagents of Herbos Diagnostika d.o.o. 
(Sisak, Croatia) manufacturer were used. To valida-
te the complete analytical performance of the 
analyser, for each method that analyzer performs 
(spectrophotometry, turbidimetry and indirect po-
tentiometry) several analytes were chosen. Met-
hods and reagents used for this validation are pre-
sented in Table 1. A commercial lyophilized control 
samples of human origin (Control Serum Level 1, 
ODC0003, lot 017; Control Serum Level 2, ODC0004, 
lot 018; ITA control serum level 1, ODC0014, lot and 
0016K ITA control serum level 2, ODC0015, lot 0017 
- Olympus Life and Material Science Europa GmbH 
(Hamburg, Germany) were used for evaluation. ITA 
control serum samples are used for CRP, RF and 
ASO, while Olympus Control Serum Level 1 and 2 
are used for all other parameters. Commercial pool 
serum prepared at the Croatian Institute of Tran-
sfusion Medicine (Zagreb, Croatia) was also used 
for the assessment. Calibrations for the tested 
analytes were performed using recommended 
procedures for the evaluated analyzer, using the 
original calibrators (System Calibrator 66300, lot 
0113D, Serum protein multi-Calibrator 1, ODR3021, 
lot 0026 and ISE low and high standard serum - Ol-
ympus Life and Material Science Europa GmbH 
(Hamburg, Germany).
Analytical evaluation
Analytical evaluation of analyzer included the de-
termination of within-run and between-run impre-
cision, inaccuracy (comparing to the declared valu-
es of the control sample) and methods comparison. 
Within-run and between-run imprecision were used 
to determine the extent of random error and accu-
racy (bias) was used to detect the extent of syste-
matic error a[ ecting the measurement (5,6).
Between-run imprecision was determined measu-
ring the concentration of analytes in the control 
sera of di[ erent concentration ranges (Level 1, Le-
vel 2, ITA 1, ITA 2) and pool serum in duplicate du-
ring the period of 30 days. Imprecision was expre-
ssed as the mean and the coej  cient of variation 
(CV%). Within-run imprecision was determined in 
duplicate on 30 consecutive measurements of dif-
ferent analyte concentrations in control sera (Level 
1, Level 2, ITA 1, ITA 2) and pool serum and also 
expressed as a coej  cient of variation (CV%).
Inaccuracy of measurement of control samples 
was shown as bias (B%), percentage of deviation of 
the analyte mean value from the control sera dec-
lared mean value. To calculate the bias, measured 
values from day-to day imprecision were used.
Obtained values for precision and bias were asse-
ssed by comparing with the speciM cations derived 
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from biological variation (7). The desirable speciM -
cations for imprecision and bias, derived from bio-
logical variation are presented in Table 2.
Comparison of results obtained on Olympus 
AU2700 plus and Olympus AU2700 analyzers was 
conducted on 50 sera samples with a wide range 
of values. The sera used for the comparison were 
collected at di[ erent hospital departments of Du-
brava University Hospital due to the routine hospi-
tal check-up of the patients. The samples were 
randomly chosen for the comparison and were 
centrifuged immediately upon the arrival in Clini-
cal Department for Laboratory Diagnostics, Du-
brava University Hospital, at 1000 x g for 15 minu-
tes in 35 R Rotina Hettich centrifuge (Tuttlingen, 
Germany). All the samples were collected in BD Va-
cutainer glass serum tubes. The commercial pool 
sera used were stored at -20°C until the analysis.
Statistical analysis
Statistical methods included the calculation of 
mean, coej  cient of variation (CV%) and bias (B%). 
Pearson correlation coej  cient and Passing-Bablok 
regression, including the Cusum test for linearity 
were calculated for the method comparison. The 
level of signiM cance was set at P < 0.01.
Statistical analysis, including descriptive statistics, 
was performed using MedCalc 9.2.0.0 software 
(MedCalc, Mariakerke, Belgium).























































Opt. UV 37°C without PF
Opt. UV 37°C without PF
IFCC Lactate NMG 37°C





















































DPD – 3.5- dichlorophenyl-diazonium-tetraR uoroborate;CHOD – cholesterol oxidase; GPO - glicerol phosphate oxisidase; TPTZ – 2.4.6- Tri-(2-
piridil)-5-triazine; Nitroso PSAP - nitroso-5-(N-propyl-N-sulfopropylamino)phenol; PF – pyridoxal phosphate; NMG – D (-) N- methylglucamine; 
NAC – N-acetylcysteine; EPS-G7 – 4.6-ethylidene(G7)-p-nitrophenyl(G1)-α-D-maltoheptaoside; pNPP-AMP – p-nitrophenyl phosphate with 2-ami-
no-2-methyl-1-propanol
Control sera for CRP, ASO and RF: ITA level 1 and 2; all other analytes: Olympus Level 1 and 2.


































































































































































Day-to-day imprecision Within-run imprecision Inaccuracy
LEVEL1 LEVEL2 POOL LEVEL1 LEVEL2 POOL LEVEL1 LEVEL2
CVw CVg I (%) B (%) CV(%) CV(%) Mean CV(%) CV(%) CV(%) Mean CV(%) B (%) B (%)
Glu 5.3 12.5 mmol/L 5.7 6.9 2.9 2.2 2.29 1.36 5.68 1.73 1.53 1.21 5.76 1.86 1.01 0.11
Crea 116 452 μmol/L 5.3 14.2 2.7 3.8 2.37 2.09 104.80 1.95 1.78 1.50 104.87 1.45 1.81 1.09
Urate 298 540 μmol/L 9.0 17.6 4.5 4.9 1.82 1.26 332.83 1.05 1.61 1.13 339.70 2.09 1.26 0.64
Bil 25.6 115 µmol/L 23.8 39.0 11.9 11.4 2.69 2.52 13.16 2.59 2.03 2.02 12.61 3.74 1.22 0.53
Chol 4.08 7.84 mmol/L 5.4 15.2 2.7 4.0 1.77 1.36 5.18 0.96 1.52 1.47 5.10 2.59 0.64 0.01
TG 1.87 3.73 mmol/L 20.9 37.2 10.5 10.7 2.69 1.81 1.35 2.01 1.93 1.72 1.47 2.04 0.59 0.84
Ca 2.26 3.30 mmol/L 1.9 2.8 1.0 0.8 1.74 1.28 2.42 0.81 1.76 1.48 2.37 1.03 0.78 0.27
IP 1.86 3.22 mmol/L 8.5 9.4 4.3 3.2 3.57 2.36 1.14 1.73 1.43 1.23 1.33 1.11 2.35 0.16
Fe 11.5 34.5 µmol/L 26.5 23.2 13.3 8.8 3.51 1.19 12.50 4.86 2.03 1.68 13.56 1.56 2.35 0.49
UIBC 23.2 44.5 µmol/L - - - - 3.90 1.93 38.04 1.61 2.22 2.12 38.27 1.40 0.68 0.18
AST 44 128 U/L 11.9 17.9 6.0 5.4 1.96 1.51 35.27 1.81 2.32 1.69 37.10 1.30 0.61 0.31
ALT 42 123 U/L 24.3 41.6 12.2 12.0 2.09 1.81 44.50 1.53 2.50 1.13 43.27 2.01 0.40 0.60
LD 151 537 U/L 8.6 14.7 4.3 4.3 3.39 1.59 230.63 2.40 1.88 1.66 226.83 1.09 1.81 0.01
CK 150 387 U/L 22.8 40.0 11.4 11.5 2.11 1.57 189.07 1.05 1.90 1.63 189.07 1.05 0.87 0.50
AMY 85 241 U/L 8.7 28.3 4.4 7.4 2.58 2.23 63.60 1.28 2.51 2.80 65.77 1.77 0.94 0.11
ALP 112 492 U/L 6.4 24.8 3.2 6.4 3.77 1.79 66.83 2.04 2.51 3.03 74.07 1.70 3.45 0.68
K 3.8 6.4 mmol/L 4.8 5.6 2.4 1.8 1.91 1.28 4.51 0.56 1.46 1.10 4.67 1.28 0.97 1.15
Na 118 149 mmol/L 0.7 1.0 0.4 0.3 1.46 1.34 140.60 0.66 1.15 1.17 145.33 1.03 0.23 1.86
Cl 90 112 mmol/L 1.2 1.5 0.6 0.5 1.50 0.97 103.53 0.75 1.58 1.05 108.70 0.94 0.52 1.31
CRP 18.3 32 mg/L 42.2 76.3 21.1 21.8 1.27 1.18 23.56 1.43 1.75 1.71 23.41 1.45 0.69 1.43
ASO 149 304 IU/L - - - - 1.67 0.83 102.45 2.36 1.60 1.23 100.97 2.90 5.41 1.73
RF 23.7 53.2 IU/ml 8.5 24.5 4.3 6.5 2.90 1.27 15.55 7.07 3.15 2.26 16.29 4.10 0.35 1.86
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Results
Results of day-to-day imprecision are shown in Ta-
ble 2. Coej  cients of variation for day-to-day im-
precision ranged as follows: in Level 1 from 1.46 % 
to 3.90%; in Level 2 from 0.97 to 2.52%; in ITA 1 
from 1.27% to 2.90%; in ITA 2 from 0.83% to 1.27% 
and in pool serum from 0.56% to 7.07%.
The results of within-run imprecision are shown in 
Table 2. Coej  cients of variation for within-run im-
precision ranged as follows: in Level 1 from 1.15% 
to 2.51%; in Level 2 from 1.05% to 3.03%; in ITA 1 
from 1.60% to 3.15%; in ITA 2 from 1.23% to 2.26% 
and for pool serum from 0.94 to 3.74%.
Test results for inaccuracy of control sera in two 
concentration levels are also shown in Table 2. For 
Level 1, bias ranged from 0.23% to 3.45%; for Level 
2 from 0.01% to 1.86%; for ITA 1 0.35 to 0.69% and 
for ITA 2 from 1.43 to 1.86%.
Comparison of the results obtained on the Olym-
pus AU2700 plus and Olympus AU2700 Olympus 
yielded the correlation coej  cients between 0.961 
and 1.000 (Table 3). The target values used for the 
calculation of inaccuracy were provided by the 
manufacturer of the commercial control sera. The 
slope and y-axis intercept as well as their respec-
tive 95% conM dence intervals (8) obtained using 
Passing-Bablok regression for all analytes are pre-
sented in Table 3.
The Cusum linearity test performed on Passing-
Bablok regression showed that there was no sig-
niM cant deviation from linearity for any analyte (P 
> 0.10) (9).
Discussion
The results of this analytical validation showed 
acceptable coej  cients of variation for day-to-day 
imprecision, within-run imprecision, as well as a 
satisfactory degree of accuracy. For setting the cri-
teria for acceptable imprecision and inaccuracy, 
we considered the biological variations of analytes 
(7,10,11). Depending on the measurement proce-
dure, measuring instruments and compliance with 
a reference or deM nitive method, we can assess 
whether the new method or analyzer is suitable 
TABLE 3. Correlation and Passing-Bablok regression data for Olympus AU2700 plus and Olympus AU2700 comparison.





































































































































P for all comparisons < 0.001.
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for routine use, and whether they are of satisfac-
tory accuracy (2,3,5,12). For most analytes tested in 
this study, the results of imprecision and bias were 
in the range of desirable speciM cations for impreci-
sion and bias, derived from biological variation 
(10,11). Bias and imprecision for sodium and chlori-
de did not fulM l required criteria. However, it is im-
portant to emphasize that these criteria are very 
strict: bias of 0.4% and 0.6% and imprecision of 
0.3% and 0.5%, for sodium and chloride, respecti-
vely. The reason for not fulM lling the desirable cri-
teria for sodium and chloride is the low biological 
variation, as well as the lack of analytical method 
capable to follow that variation with the results 
that are precise and accurate enough. However, la-
boratories must be aware of this limitation, and 
ensure smaller measurement uncertainty using 
quality control tools (participation in external qua-
lity control assessment, control of preanalytical 
and postanalytical phase) (13,14).
Correlation analysis yielded high correlation coef-
M cients proving high correlation for all the tested 
parameters.
Passing-Bablok regression showed that most anal-
ytes did not di[ er by a constant (95% CI of inter-
cept includes 0), and that were well aligned, sug-
gesting that there were no proportional di[ eren-
ces between methods (95% CI of slope includes 1) 
(9). Despite of high correlations, some analytes did 
not meet the preferences of Passing-Bablok regre-
ssion. When following Passing-Bablok regression 
strict criteria, ALT, RF, and sodium di[ ered by a 
constant amount for both analyzers and the pro-
portional di[ erence between methods was found 
for CK, total bilirubin and triglycerides (Table 3). 
Passing-Bablok regression yielded a wide range of 
95% CI of intercept for sodium, and that should 
also be considered when deM ning the analytical 
objectives. Unlike sodium, ALT and RF are a bit 
beyond the requested criteria (95% CI of intercept 
for ALT was 0.290-1.000 and 0.677-1.377 for RF), so 
in the analytical sense, those analytes follow the 
same linearity. Similar is the case with the CK, total 
bilirubin and triglycerides whose 95% CI of slope 
was very close to 1 (1.014-1.022, 1.007-1.046 and 
0.944-0.985 respectively), therefore the analysis 
can be considered acceptably aligned.
Conclusion
Olympus AU2700 plus analytical analyzer shows 
acceptable precision and accuracy for majority of 
analytes, with the exception of sodium and chlori-
de. Instrument is fully comparable with Olympus 
AU2700 analytical analyzer for all but several anal-
ytes (ALT, RF, sodium, CK, total bilirubin and trygli-
cerides) where only some minor deviations (con-
stant and proportional di[ erence) were observed.
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Analitička procjena analizatora Olympus AU2700 plus
Sažetak
Uvod: Cilj ovog ispitivanja bio je provesti analitičku procjenu analizatora Olympus AU2700 plus za pretrage iz kliničke kemije. Procjena je naprav-
ljena prema smjernicama Europskog povjerenstva za standarde kliničkih laboratorija (engl. European Committee for Clinical Laboratory Standards, 
ECCLS).
Materijali i metode: Procjenjivalo se određivanje nepreciznosti u seriji i iz dana u dan, netočnost i korelacija s analizatorom Olympus AU2700. 
Ispitani analiti bili su: glukoza, kreatinin, urat, ukupni bilirubin, kolesterol, trigliceridi, kalcij, fosfat, željezo, nezasićeni kapacitet vezanja željeza, 
aspartat-aminotransferaza, alanin-aminostransferaza, laktat-dehidrogenaza, kreatinin-kinaza, alfa-amilaza, alkalna fosfataza, kalij, natrij, klo-
rid, C-reaktivni protein, antistreptolizin O i reumatoidni faktor.
Rezultati: Rezultati ispitivanja su za sve analite pokazali nisku nepreciznost u seriji i iz dana u dan te prihvatljivu netočnost. Primijećena je visoka 
korelacija s analizatorom AU2700. Vrijednosti odsječka i nagiba pravca (s intervalom pouzdanosti od 95%) zadovoljili su kriterije regresijske anali-
ze po Passing-Babloku za sve analite osim za alanin-aminotransferazu, natrij, reumatoidni faktor, kreatin-kinazu, ukupni bilirubin i trigliceride.
Zaključak: Analizator Olympus AU2700 plus pokazuje prihvatljivu preciznost i točnost za većinu analita s iznimkom natrija i klorida. Instrument 
je potpuno usporediv s analizatorom Olympus AU2700 za sve analite osim njih nekoliko (ALT, RF, natrij, CK, ukupni bilirubin i trigliceridi) gdje se 
pojavljuju samo manja odstupanja (konstantna i proporcionalna razlika).
Ključne riječi: Olympus A2700 plus; analitička procjena; nepreciznost; netočnost; regresijska analiza po Passing-Babloku
